Carmel, Ralph: Artifactual radioassay results due to serum contamination by intravenous radioisotope administration. Falsely low serum vitamin B l2 and folic acid results. Am J Clin Pathol 70: 364-367, 1978. Radioisotopic contamination by recent radiosotope administration (either "'""technetium or "gallium) to the patient for scanning purposes was found in 28 sera submitted for vitamin B 12 or folic acid assay, or both, during the year prior to this study. In half the cases serum radioactivity was so great as to be readily identifiable during the assay. In the rest, however, the radioactivity would not have been detected had serum supernatant blanks not been routinely incorporated in the assay procedure. Many radioassay kits make no provision for such supernatant control blanks. Were it not for these blanks, five patients would have been falsely identified as vitamin B ^-deficient and three others as possibly deficient in the present series. Two of the five radioactive sera assayed for folate would also have given misleading results in the borderline-low range. The clinician should avoid ordering tests requiring radioassay when the patient has been given radioisotopes, and those performing radioassays must institute appropriate maneuvers to detect any such contamination. (Key words: Artifactual radioassay results; Serum vitamin B, 2 ; Folic acid, Radioassay.) THE DIAGNOSTIC USE of radioisotopes has burgeoned during the past decade. In-vivo organ scanning has become commonplace, and many in-vitro radioimmunoassay and competitive protein-binding radioisotopic methods have been developed to measure levels of drugs, hormones, vitamins, and other substances. This communication demonstrates one source of artifact which, with the increasing use of radioisotopes, is seen more frequently and should be kept in mind by both the clinician and the diagnostic laboratory. The artifact was detected during the performance of routine radioisotopic vitamin B l2 and occasional radioisotopic folate assays in the laboratory. Similar problems probably apply to many other radioassays, though individual details may vary. The findings illustrate the problem created by the increasing frequency of radioisotopic contamination of serum samples, which is of-
ten inadequately appreciated, and identify some of the possible steps to detect and correct such artifact.
Materials and Methods
Serum samples have been assayed for vitamin B 12 levels routinely, as requested by managing physicians at the Los Angeles County-USC Medical Center. Assay procedure follows the radioisotope dilution method of Lau and associates. 9 The only modification has been to use saliva instead of intrinsic factor as the 5 7 Co-B 12 ligand.
2 All sera were assayed in duplicate, with a third test tube as the serum supernatant control blank to correct for undenatured vitamin B, 2 -binding capacity of the serum itself. Saliva was not added to this control tube, and its radioactivity was subtracted from that of the serum duplicates. The 5 7 Co-B 1 2 (10-15 fxCi/fJig) was obtained from Amersham Searle Corporation,* and the radioactivity was counted in a well-type gamma scintillation countert with settings to detect an energy range of 50-200 keV. Samples were counted for a minimum of 2 minutes each. Whenever the radioactivity of a serum supernatant control tube exceeded 600 counts per minute, we counted the original serum to determine whether it contained endogenous radioactivity.
Although my laboratory routinely performs serum folic acid assays microbiologically, 6 we also assayed occasional samples radioisotopically using a 3 H-labeled folic acid radioassay kit.t The radioassay was done exactly as recommended by the manufacturer, except that the buffer pH was adjusted to 9.3 instead of 9.2. No provision had been made for serum supernatant con- • Normal = 150-900 pg/ml. t The number in parentheses is the interval in days from isotope injection to assay date. The preceding number is the interval in days from injection to the date the blood sample was obtained.
t Vitamin B" level "less than zero." Radioactivity in these sera was so high that it exceeded the 100% binding level. The contamination, therefore, would have been recognizable in these sera even had the serum supernatant control tube been omitted. § Data unobtainable.
trol tubes. The samples were counted in a Unilux II liquid scintillation counter. § Sera found to be radioactive were further studied by reassay after radioactivity had decayed to the point where it became undetectable and in two cases by obtaining follow-up blood samples. Patient records were reviewed to ascertain details of radioisotope administration; in only two cases were such data not available.
Results
Endogenous radioactivity was found in 28 serum samples submitted over a 12-month period. For 26 of these specimens, vitamin B I2 assay had been requested, § Nuclear-Chicago, Searle Analytic Inc., Des Plaines, Illinois. 8 (11) 1 (7) 99m "pQ 99m Tc C7 Ga " m Tc fl7 Ga 99m Tc 87 Ga * Normal = 5-25 ng/ml; indeterminate = 3-5 ng/ml. t The number in parentheses is the interval in days from isotope administration to assay date. The preceding number is the interval in days from administration to the date the blood sample was drawn.
t Folic acid level "less than zero." Radioactivity in these sera was so high that it exceeded the 100% binding level. Since serum supernatant control blank was not incorporated in the assays, only these sera could be readily identified as contaminated. and five were tested by folate radioassay (both assays were done on three of these sera). Endogenous radioactivity was confirmed in all cases by counting serum samples directly.
Vitamin B i2 Radioassay (Table 1) . Both 9Bm technetium (injected as glucoheptonate for brain scan, or in several cases as the sulfur colloid for liver scan) and 67 gallium (injected as citrate for body scanning) administration resulted in retention in serum of gammaemitting isotope that interfered with the vitamin B 12 radioassay. The 15 sera in which 99m Tc was the contaminant were all obtained within one day of its administration, though the samples themselves remained radioactive as long as five days thereafter. However, in one case (Patient 12) a follow-up serum specimen drawn four days after isotope administration was no longer radioactive. The nine sera in which 67 Ga, alone or together with a second isotope, was the contaminant were obtained one to nine days after administration; and the samples themselves remained radioactive as long as 11 days thereafter. In one case (Patient 24) follow-up blood samples were obtained and showed persistent retention of isotope for at least fourteen days after injection.
Assay results were calculated with correction for the serum radioactivity apparent in the serum supernatant control tube and agreed closely with those obtained on reassay after the sera were no longer radioactive in 20 of the 23 cases where this was done. In three cases reassay produced values that were lower (Patient 5: 332 pg/ml; Patient 18: 164 pg/ml; Patient 20: 568 pg/ml).
In 13 of the 26 sera, the very high radioactivity obtained in the duplicate assay tubes clearly indicated the presence of contaminating isotope. However, in
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the other 13 sera the total radioactivity was low enough so that, had it not been for the serum supernatant blank, the presence of contaminating isotope would not have been detected. The results therefore would have been erroneous for the latter 13 sera if the serum supernatant blank had been omitted and contamination thereby not recognized. Since the nature of the radioisotope dilution assay is such that final radioactivity is inversely proportional to the level of the assayed substances, falsely lower vitamin B 12 levels would have been obtained. In fact, in five cases (Patients 13, 16, 18 , 21, and 25) vitamin B 12 deficiency would have been falsely suggested, and in three others (Patients 3, 11, and 26) borderline-low levels would have been reported.
Folic Acid Radioassay (Table 2 ). Excessively high radioactivity was readily recognizable in three cases. However, in two others (Patients 11 and 12) only awareness of endogenous radioactivity detected during vitamin B, 2 assay of the same serum led to recognition of folate assay artifact. In both of the latter cases, folate levels misleadingly appeared to be in the borderline-low range. Concurrent microbiologic assay, however, revealed true levels that were normal in these two patients, as well as in the other three in the series. Two patients had been given Ga only. Intervals from isotope administration to blood sample drawing ranged from less than one to seven days.
Discussion
The two isotopes currently most commonly used for scanning procedures are Ga. Both are gamma emitters whose energy peaks are very similar to that of 57 Co.
67
Ga has a relatively slow clearance from the blood (5% of the radioactivity remains after 48 hours) 3 and is protein-bound, though the nature of the binding protein is disputed.
-5 99m
Tc has a much shorter half-life and faster clearance, 1,7,s and 3-4% of the radioactivity has been estimated to remain circulating after 24 hours, 10 though much of that may have actually been bound to erythrocytes. Most of the isotope is protein-bound. 7 Thus, it was not surprising that contamination of serum with either or both of the isotopes used for scanning produced falsely high " 57 Co" counts. Such contamination was found in sera obtained as long as 14 days after 67 Ga administration, though usually not much more than one day after 99m Tc administration. It appears that the extent of contamination depends on both the half-life and the extent of binding of the isotope.
Since the result in the radioisotope dilution assay technic is inversely related to radioactivity, falsely low vitamin levels resulted. In half of these cases, the radioactivity was extremely high and the readings were therefore off the scale. Such contamination was thus readily recognizable even without supernatant blanks. However, in the rest contamination would not have been identified without supernatant blanks, a finding particularly significant because the commercial kits being used by most clinical laboratories make no provision for such blanks. While it may appear that the magnitude of the problem is not significant (during the period covered by the present study, approximately 2,000 serum samples had been submitted for vitamin B 12 assay), the opposite is true from the clinical standpoint, because the artifact produces lowered results and therefore disproportionately affects the end of the scale considered abnormal. Thus, five patients would have been falsely identified as vitamin B 12 -deficient and three others as possibly deficient, a sizable number when compared with the 26 cases found to be truly vitamin B 12 -deficient during this period.
Assays using other radioisotopes in vitro may be similarly affected by isotope injection, depending on the assay separation steps and other details. Thus, 67 Ga injection was recently reported to cause either a falsepositive or a false-negative anti-DNA antibody radioassay result, depending on the assay method used." It should also be noted that 125 I has an energy peak slightly overlapping those of the above-mentioned isotopes, and a serum contaminated with 67 Ga and 99m Tc gave elevated counts when counted for l25 I. Somewhat unexpected was the finding that the folate assay, using 3 H, was also affected, since isotopes used in scanning procedures are primarily gamma emitters. However, 67 Ga and 99m Tc also emit beta particles. 4 Had folate assay usually been done isotopically instead of microbiologically in my laboratory, many more than just five sera would certainly have been found to produce artifact.
Thus, it is incumbent on clinicians to be aware of the serum contamination possible for several days after in-vivo isotopic scanning procedures and the possible effect of this contamination on the ever-increasing number and variety of radioisotopic assays available. Both Jfje potential diagnostic errors and the economic wastefulness of repeating the assays subsequently must be considered, and test ordering should be modified accordingly. Similarly, those performing the assays should either screen all submitted samples for radioactivity or include appropriate serum supernatant control tubes in their assays.
